On May 21, 2026 AbbVie (NYSE: ABBV) reported that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline. The data will be shared through multiple oral presentations and posters spanning solid tumors and blood cancer indications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Collectively, these presentations highlight AbbVie’s continued focus on attacking cancer from inside and outside the cell, supported by sustained investment in its expanding antibody‑drug conjugate (ADC) platform, including Topoisomerase I inhibitor (Top1i)–based ADCs and its T‑cell engager (TCE) portfolio.
"Our oncology pipeline is intentionally designed to address the complexity and heterogeneity of cancer biology through a diversified portfolio of differentiated therapies spanning multiple modalities," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology. "The data we are presenting at ASCO (Free ASCO Whitepaper) reflect the strength of this strategy, including continued momentum with our ADC programs in solid tumors and validation of immune-based approaches, such as etentamig, being investigated as a next-generation TCE in multiple myeloma. These results underscore our commitment to advancing assets with distinct scientific approaches aimed to address critical unmet patient needs."
Key findings presented include:
Data from AbbVie’s Top1i ADCs Across Solid Tumors:
Metastatic castration-resistant prostate cancer (mCRPC): A first-in-human Phase 1 study (NCT06318273) evaluating ABBV-969, a potential first-in-class bispecific ADC targeting PSMA/STEAP1, in heavily pretreated patients with mCRPC, demonstrated a confirmed objective response rate (ORR) of 45% among 29 patients with RECIST-evaluable disease. At active dose levels, 67% of patients achieved at least a 50% reduction in prostate-specific antigen (PSA50), with 28% achieving PSA90 responses. The safety profile was manageable in heavily pretreated patients with mCRPC.1 Additional findings to be presented at the meeting.
Small cell lung cancer (SCLC): In Phase 1 data (NCT05599984) of ABBV-706 (SEZ6-directed ADC) in the monotherapy cohort (n=17), SCLC patients receiving ABBV-706 at the recommended Phase 3 dose of 1.8 mg/kg as a second-line therapy achieved an objective response rate (ORR) of 82%— promising data in a disease where prognosis remains poor. The safety profile was comparable with previously reported data.2 Additional findings and updated data will be presented at the meeting. The findings support continued evaluation of ABBV-706 in SCLC.
Platinum-resistant ovarian cancer (PROC) and head and neck squamous cell carcinoma (HNSCC): Data from a Phase 1 basket study of Telisotuzumab adizutecan (Temab-A), a next-generation c-Met–directed ADC, demonstrated antitumor activity of Temab-A monotherapy in biomarker unselected PROC (NCT06084481) and HNSCC (NCT06084481) patients.3,4
Additional observations in c-Met selected patients, to be presented at the meeting, highlight the potential of Temab-A in this population.3,4
These new data support the potential of Temab-A across an expanding range of solid tumors and patient populations, including previously presented data in lung, colorectal and gastric cancers and across patients with MET-amplification and increased c-Met expression.
Relapsed/refractory multiple myeloma (R/R MM): Data from a Phase 1b study of etentamig (NCT05650632), being investigated as a next-generation B-cell maturation antigen (BCMA) x CD3 T-cell engager, as monotherapy in a cohort of heavily pre-treated BCMA-exposed R/R MM patients will be presented at the meeting.
Etentamig is an investigational BCMA and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.
The data showed that among patients (n=11) that proceeded to etentamig after BCMA-directed CAR-T in the prior line of therapy, an ORR of 64% was achieved. Minimal residual disease (MRD) negativity was observed in 67% (2/3) of evaluable patients who received BCMA-directed therapy in the prior line of therapy. The median duration of response was 13 months. No new safety signals were observed. Despite no step-up dosing (SUD) in this cohort, all cytokine release syndrome (CRS) reported (57%) were grade 1 and 2.5 Additional findings to be presented at the meeting.
Further information on AbbVie clinical trials is available at View Source
Additional details on key presentations are available below, and the full ASCO (Free ASCO Whitepaper) Annual Meeting 2026 abstracts are available here.
Title
Date/Time
Session
Abstract
Number
Etentamig in patients (pts) with
relapsed/refractory multiple
myeloma (RRMM) with prior
exposure to B-cell maturation
antigen (BCMA)-targeted therapy.
Friday,
May 29
5:09-5:21
PM CDT
Oral Presentation
Oral Abstract
Session
Hematologic
Malignancies—
Plasma Cell
Dyscrasia
7508
Phase 1 basket study of
telisotuzumab adizutecan
(Temab-A, ABBV-400), a
c-Met protein-targeting antibody-
drug conjugate: Results from
patients with platinum-resistant
ovarian/primary
epithelial/fallopian tube cancer
(PROC).
Saturday,
May 30
8:42-8:48
AM CDT
Rapid Oral
Abstract Session
Gynecologic
Cancer
5514
A phase 2 randomized study
comparing telisotuzumab
adizutecan monotherapy with
standard of care in patients with
post-adjuvant circulating tumor
DNA-positive colorectal cancer.
Saturday,
May 30
9:00 AM-
12:00 PM
CDT
Poster Board:
447a
Poster Session
Gastrointestinal
Cancer—Colorectal
and Anal
TPS3688
A Phase 2 study of telisotuzumab
adizutecan (ABBV-400; Temab-A)
in patients with advanced solid
tumors harboring MET
amplification.
Saturday,
May 30
1:30-4:30
PM CDT
Poster Board:
293a
Poster Session
Developmental
Therapeutics—
Molecularly
Targeted Agents
and Tumor Biology
TPS3157
Phase 1 basket study of
telisotuzumab adizutecan (ABBV-
400, Temab-A), a c-Met protein-
targeting antibody-drug
conjugate: Results from patients
with head and neck squamous
cell carcinoma (HNSCC).
Saturday,
May 30
1:30-4:30
PM CDT
Poster Board:
484
Poster Session
Head and Neck
Cancer
6027
Telisotuzumab adizutecan
(Temab-A) plus osimertinib (osi)
as 1L treatment for
unresectable/metastatic NSCLC.
Sunday,
May 31
9:00 AM-
12:00 PM
CDT
Poster Board:
451a
Poster Session
Lung Cancer—
Non-Small Cell
Metastatic
TPS8663
Impact of MET amplification
(amp) on telisotuzumab vedotin
(Teliso-V) efficacy and safety in
2L+ non-squamous (NSQ) EGFR
wild-type (WT) NSCLC with c-Met
protein overexpression (OE).
Sunday,
May 31
9:00 AM-
12:00 PM
CDT
Poster Board: 314
Poster Session
Lung Cancer—
Non-Small Cell
Metastatic
8524
AndroMETa-Lung-713: A phase
2/3 study of telisotuzumab
adizutecan (ABBV-400, Temab-A)
vs standard of care (SOC) in
patients with epidermal growth
factor receptor (EGFR)-mutated
non-small cell lung cancer
(NSCLC).
Sunday,
May 31
9:00 AM-
12:00 PM
CDT
Poster Board:
450a
Poster Session
Lung Cancer—
Non-Small Cell
Metastatic
TPS8661
SEZanne: A phase 2 randomized,
open-label, multicenter study to
evaluate the optimal dose, safety,
and efficacy of ABBV-706 in
combination with atezolizumab
(atezo) versus standard of care
(SOC) in patients (pts) with
previously untreated extensive-
stage (ES) small cell lung cancer
(SCLC).
Sunday,
May 31
9:00 AM-
12:00 PM
CDT
Poster Board:
603a
Poster Session
Lung Cancer—Non-
Small Cell Local-
Regional/Small
Cell/Other
Thoracic Cancers
TPS8135
A phase 1, first-in-human (FIH)
study evaluating the safety,
pharmacokinetics, and efficacy of
ABBV-969 in patients with
metastatic castration-resistant
prostate cancer (mCRPC).
Sunday,
May 31
4:42-4:48
PM CDT
Rapid Oral
Abstract Session
Genitourinary
Cancer—Prostate,
Testicular,
and Penile
5014
A single-arm, phase 2 study of
neoadjuvant mirvetuximab
soravtansine and carboplatin for
FRα-expressing advanced-stage
serous epithelial ovarian, fallopian
tube, or primary peritoneal cancer
(M25-231; NCT06890338; GOG-
3115).
Monday,
June 1
9:00 AM-
12:00 PM
CDT
Poster Board:
296b
Poster Session
Gynecologic
Cancer
TPS5633
ABBV-706 as monotherapy and in
combination with budigalimab in
patients with relapsed/refractory
(R/R) small cell lung cancer (SCLC).
Monday,
June 1
3:39-3:51
PM CDT
Oral Presentation
Oral Abstract
Session
Lung Cancer—Non-
Small Cell Local-
Regional/Small
Cell/Other
Thoracic Cancers
8008
Phase 1, first-in-human (FIH)
study evaluating safety and
efficacy of ABBV-706: Results
from patients with high-grade
central nervous system (CNS)
tumors.
Monday,
June 1
1:30-4:30
PM CDT
Poster Board: 406
Poster Session
Central Nervous
System Tumors
2041
A US-based, retrospective,
observational study of biomarker
testing patterns across lines of
therapy in patients with
metastatic colorectal cancer.
N/A
Publication Only
Gastrointestinal
Cancer –
Colorectal and
Anal
e15526
Timing of biomarker testing and
associated clinical outcomes in
ovarian cancer patients: A
retrospective study.
N/A
Publication Only
Gynecologic
Cancer
e17574
Real-world (RW) characteristics
and outcomes in platinum-
resistant ovarian cancer (PROC)
patients treated with
mirvetuximab soravtansine
(MIRV) monotherapy or single-
agent chemotherapy (CTx).
N/A
Publication Only
Gynecologic
Cancer
e17606
Telisotuzumab adizutecan (Temab-A), etentamig, ABBV-969, and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.
U.S. Prescribing Information for AbbVie Medicines
Please see full Prescribing Information for ELAHERE (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS (telisotuzumab vedotin-tllv)
Please see full Prescribing Information for EPKINLY (epcoritamab -bysp)
(Press release, AbbVie, MAY 21, 2026, View Source [SID1234665956])